believ market enthusiast mylan
disappoint result think reason stock close
new guidanc much lower consensu
mani investor saw clear event base
discuss client investor seem concern
whether set beat quarter compar overal
valuat progress busi lower ep
estim new price target vs previou
review issu august note
disclos juli compani
enter agreement purchas world-wide right
commerci product approxim million mylan
expect close transact second half
awar issu press releas transact
believ investor know detail
deal especi given size accret may mean
mylan guidanc lower may conserv
news cover press releas result
includ includ april certain
employe serv search warrant
issu public prosecutor offic milan itali seek
inform concern interact italian hospit sale
certain reimburs drug compani
assist employe cooper investig
addit may subsidiari
receiv civil investig demand civil divis
doj seek inform relat price sale
far repurchas million share note
repurchas approxim million share
approxim million estim
lower number share vs repres
approxim benefit ep
lower ep estim beyond new
price target believ investor see new
guidanc clear event view likelihood
compani beat number go forward increas given lower
guidanc us north american sale concern
advair gener off-set
concern base busi us deterior
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani prioriti stock list
compani data secur llc estim reuter
look back histori
think import investor know rememb histori earn guidanc
view recent earn guidanc revis context previou earn guidanc billion
dollar accret acquisit
adjust dilut ep least
least ep present also includ expect
launch gener advair cite us brand advair market billion
approxim billion assum epipen gener
state saw potenti acceler achiev adjust ep
target announc deal buy number abbott asset
billion believ transact give potenti acceler previous
state financi target includ least adjust ep
least adjust ep
march report billion adjust net earn guid
adjust net earn billion ep
feb report result adjust earn billion
ep provid guidanc billion billion
re-affirmed adjust ep
august guid ep estim would translat approxim
billion adjust earn midpoint ep
compani file factset secur llc estim
reason provid histori appear us histori set near- longer-
term financi target strateg goal end miss whether ep
target repeat sever year recent ep guidanc
miss origin target set compani
note larg execut team made ep target later
abandon team reiter ep guidanc three
month ago lower think histori earn revis
reflect posit compani
first made ep goal manag state
intern opportun show today believ achiev earn per
share per share elsewher day state confid target start
point power like noth go get alreadi
want model say well get thing come
feel fairli confid even beat
look back see sinc make origin goal ep undertaken
billion acquisit includ abbott gener approxim billion fami
approxim billion despit billion deal ep target rais
lower sever deal announc said accret earn find
well short goal disappoint view
believ lot go good list pipelin gener biosimilar program
near-term catalyst approv long-await gener advair said sinc
consensu current oper margin go approxim
know market fulli anticip sinc mani program partner
may result lower-than-compani averag margin addit epipen epipen gener
big use think impact gener epipen may reflect
investor expect believ could potenti event
like like new guidanc might conserv howev
concern overarch concern histori miss long-term target near-term
earn guidanc reflect either inabl forecast accur busi make
accur forecast difficult would want larger discount consid fair valu
warrant upgrad share els equal maintain market perform
factset secur llc estim
million unless otherwis note
compani file factset secur llc estim
previou new incom segment revenu north rest chg segment revenu north rest profit expens expens interest incom incom incom per specialti pharmaceut
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like less favor prior
year gener compani may less polit cover go forward gener drug
penetr may alreadi peak epipen concentr sale profit govern risk
sec investig lawsuit integr risk tie meda deal
remain market perform believ face anoth potenti headwind gener a/b
rate epipen emerg believ like also believ gener sector
rapid margin-declin environ caution warrant
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
